Unmet Needs With Car T Therapy in Multiple Myeloma: Nina Shah, MD

Video

The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Nina Shah, MD, hematologist/oncologist and associate professor of medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, about unmet needs with CAR T-cell therapy in multiple myeloma.

Shah discussed how CAR T-cell therapy has not quite managed to cure patients with multiple myeloma and no plateau has been seen on the survival curves, although the therapies have been a welcome addition to the treatment landscape. Innovative ways to prolong the efficacy of CAR T-cell therapy are being investigated, Shah said.

Unique culturing techniques, such as those utilized with the investigational bb21217 product, are being evaluated. Additionally, engineering techniques aimed at increasing the T-stem cell–like memory phenotype are being studied with the P-BCMA-101 product. Finally, allogenic CAR T-cell therapies, such as those being developed by Allogene Therapeutics, have the potential to increase accessibility to CAR T-cell therapy in multiple myeloma, Shah explained.

Ultimately, refining the culturing, engineering, and manufacturing process of CAR T-cell therapy may improve the success of this therapeutic modality and provide prolonged responses to patients with multiple myeloma, Shah concluded.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
© 2024 MJH Life Sciences

All rights reserved.